Boston Scientific Corp. forked over up to $160 million to acquire California stent maker Veniti Inc. The deal marks the third acquisition for Boston Scientific in two months.
The Spanish pharmaceutical company Almirall agreed to buy five dermatology brands from U.S. company Allergan for up to $650 million in cash.
Bayer agreed to sell the German drugmaker’s established prescription dermatology brands to Denmark’s Leo Pharma.
The U.S. Justice Department will not challenge the $69 million merger of CVS Health and health insurer Aetna.
Tokyo’s Otsuka Pharmaceutical is acquiring Waltham, Mass.-based Visterra for $430 million in cash. The deal is expected to close during third-quarter 2018.
CURE Pharmaceutical signed a term sheet to acquire the non-pain assets of Therapix Biosciences.
Catalent Inc. announced that the drug delivery company agreed to acquire Juniper Pharmaceuticals Inc., including its Nottingham, U.K.-based Juniper Pharma Services division.
Data foundation Acxiom announced a definitive agreement to sell its Acxiom Marketing Solutions business to Interpublic Group for $2.3 billion in cash.
Adamis Pharmaceuticals is selling U.S. commercial rights to Symjepi, a competitor to Mylan’s EpiPen, to Novartis.
Akebia Therapeutics announced a merger agreement with Keryx Biopharmaceuticals to create a company expected to be a leader in the development of renal disease therapies.